Corcept Therapeutics Incorporated (NASDAQ:CORT) Ends Optime Pact And Enters Transitionary Commercial Phase
![]() |
Operational shifts and active litigation place Corcept in a transitionary commercial phase with near-term momentum tied to distribution and legal developments. Market valuation sits well above typical biotechnology peers, amplifying sensitivity to upcoming operational and regulatory milestones. |










